AngioDynamics Inc (ANGO) - Net Assets
Based on the latest financial reports, AngioDynamics Inc (ANGO) has net assets worth $170.82 Million USD as of May 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($267.16 Million) and total liabilities ($96.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AngioDynamics Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $170.82 Million |
| % of Total Assets | 63.94% |
| Annual Growth Rate | N/A |
| 5-Year Change | -59.76% |
| 10-Year Change | -66.96% |
| Growth Volatility | 489.34 |
AngioDynamics Inc - Net Assets Trend (2002–2026)
This chart illustrates how AngioDynamics Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see ANGO stock market capitalisation.
Annual Net Assets for AngioDynamics Inc (2002–2026)
The table below shows the annual net assets of AngioDynamics Inc from 2002 to 2026. Also explore ANGO shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-05-31 | $170.82 Million | -6.64% |
| 2025-05-31 | $182.97 Million | -11.00% |
| 2024-05-31 | $205.59 Million | -45.65% |
| 2023-05-31 | $378.30 Million | -10.88% |
| 2022-05-31 | $424.49 Million | -3.41% |
| 2021-05-31 | $439.46 Million | -3.60% |
| 2020-05-31 | $455.87 Million | -25.85% |
| 2019-05-31 | $614.82 Million | +13.31% |
| 2018-05-31 | $542.60 Million | +4.95% |
| 2017-05-31 | $517.03 Million | +1.97% |
| 2016-05-31 | $507.03 Million | -6.97% |
| 2015-05-31 | $545.02 Million | +1.33% |
| 2014-05-31 | $537.89 Million | +2.10% |
| 2013-05-31 | $526.83 Million | +0.66% |
| 2012-05-31 | $523.39 Million | +28.99% |
| 2011-05-31 | $405.75 Million | +3.68% |
| 2010-05-31 | $391.35 Million | +5.15% |
| 2009-05-31 | $372.19 Million | +4.63% |
| 2008-05-31 | $355.71 Million | +5.88% |
| 2007-05-31 | $335.96 Million | +172.17% |
| 2006-05-31 | $123.44 Million | +151.35% |
| 2005-05-31 | $49.11 Million | +31.90% |
| 2004-05-31 | $37.23 Million | +2402.15% |
| 2003-05-31 | $1.49 Million | +604.41% |
| 2002-05-31 | $-295.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to AngioDynamics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 45381000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (May 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $387.00K | 0.23% |
| Other Comprehensive Income | $7.67 Million | 4.49% |
| Other Components | $628.70 Million | 368.04% |
| Total Equity | $170.82 Million | 100.00% |
AngioDynamics Inc Competitors by Market Cap
The table below lists competitors of AngioDynamics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
New Trend International Logis-Tech Co Ltd
SHE:300532
|
$648.31 Million |
|
General Interface Solution GIS Holding Ltd
TW:6456
|
$648.35 Million |
|
JBG SMITH Properties
NYSE:JBGS
|
$648.39 Million |
|
eXp World Holdings, Inc.
NASDAQ:AGNT
|
$648.42 Million |
|
Turaco Gold Ltd
AU:TCG
|
$648.05 Million |
|
M Grass Ecology and Environment Group Co Ltd
SHE:300355
|
$647.91 Million |
|
Rashtriya Chemicals and Fertilizers Limited
NSE:RCF
|
$647.88 Million |
|
ZheJiang RIFA Digital Precision Machinery Co Ltd
SHE:002520
|
$647.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AngioDynamics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 182,970,000 to 170,825,000, a change of -12,145,000 (-6.6%).
- Net loss of 36,742,000 reduced equity.
- Other comprehensive income increased equity by 9,698,000.
- Other factors increased equity by 14,899,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-36.74 Million | -21.51% |
| Other Comprehensive Income | $9.70 Million | +5.68% |
| Other Changes | $14.90 Million | +8.72% |
| Total Change | $- | -6.64% |
Book Value vs Market Value Analysis
This analysis compares AngioDynamics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.81x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-05-31 | $-0.03 | $15.68 | x |
| 2003-05-31 | $0.16 | $15.68 | x |
| 2004-05-31 | $3.78 | $15.68 | x |
| 2005-05-31 | $3.98 | $15.68 | x |
| 2006-05-31 | $9.52 | $15.68 | x |
| 2007-05-31 | $18.22 | $15.68 | x |
| 2008-05-31 | $14.61 | $15.68 | x |
| 2009-05-31 | $15.18 | $15.68 | x |
| 2010-05-31 | $15.79 | $15.68 | x |
| 2011-05-31 | $16.14 | $15.68 | x |
| 2012-05-31 | $20.62 | $15.68 | x |
| 2013-05-31 | $15.13 | $15.68 | x |
| 2014-05-31 | $15.18 | $15.68 | x |
| 2015-05-31 | $15.27 | $15.68 | x |
| 2016-05-31 | $14.02 | $15.68 | x |
| 2017-05-31 | $13.99 | $15.68 | x |
| 2018-05-31 | $14.45 | $15.68 | x |
| 2019-05-31 | $16.40 | $15.68 | x |
| 2020-05-31 | $12.01 | $15.68 | x |
| 2021-05-31 | $11.46 | $15.68 | x |
| 2022-05-31 | $10.88 | $15.68 | x |
| 2023-05-31 | $9.58 | $15.68 | x |
| 2024-05-31 | $5.12 | $15.68 | x |
| 2025-05-31 | $4.46 | $15.68 | x |
| 2026-05-31 | $4.11 | $15.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AngioDynamics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -11.48%
- • Asset Turnover: 1.20x
- • Equity Multiplier: 1.56x
- Recent ROE (-21.51%) is below the historical average (-3.24%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 0.00% | 3.27% | 1.50x | 0.00x | $1.04 Million |
| 2003 | 79.70% | 3.09% | 1.42x | 18.18x | $1.04 Million |
| 2004 | 8.44% | 6.41% | 0.99x | 1.34x | $-580.20K |
| 2005 | 9.26% | 7.54% | 1.01x | 1.22x | $-363.00K |
| 2006 | 5.56% | 8.75% | 0.57x | 1.11x | $-5.48 Million |
| 2007 | -2.72% | -8.13% | 0.29x | 1.14x | $-42.72 Million |
| 2008 | 3.06% | 6.54% | 0.41x | 1.15x | $-24.68 Million |
| 2009 | 2.67% | 5.09% | 0.48x | 1.10x | $-27.29 Million |
| 2010 | 3.15% | 5.70% | 0.51x | 1.08x | $-26.82 Million |
| 2011 | 2.00% | 3.76% | 0.49x | 1.08x | $-32.46 Million |
| 2012 | -0.99% | -2.34% | 0.31x | 1.39x | $-57.52 Million |
| 2013 | -0.23% | -0.35% | 0.43x | 1.50x | $-53.89 Million |
| 2014 | 0.44% | 0.66% | 0.44x | 1.49x | $-51.44 Million |
| 2015 | -0.62% | -0.95% | 0.46x | 1.42x | $-57.89 Million |
| 2016 | -8.60% | -12.32% | 0.49x | 1.44x | $-94.29 Million |
| 2017 | -1.36% | -2.02% | 0.49x | 1.37x | $-58.75 Million |
| 2018 | 3.01% | 4.74% | 0.49x | 1.30x | $-37.92 Million |
| 2019 | 9.98% | 17.06% | 0.43x | 1.36x | $-141.50K |
| 2020 | -36.59% | -63.14% | 0.44x | 1.31x | $-212.37 Million |
| 2021 | -7.18% | -10.84% | 0.52x | 1.28x | $-75.49 Million |
| 2022 | -6.25% | -8.40% | 0.57x | 1.30x | $-69.00 Million |
| 2023 | -13.86% | -15.48% | 0.64x | 1.41x | $-90.27 Million |
| 2024 | -89.67% | -60.66% | 0.96x | 1.55x | $-204.91 Million |
| 2025 | -18.58% | -11.62% | 1.04x | 1.53x | $-52.29 Million |
| 2026 | -21.51% | -11.48% | 1.20x | 1.56x | $-53.82 Million |
Industry Comparison
This section compares AngioDynamics Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,166,957,667
- Average return on equity (ROE) among peers: -153.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AngioDynamics Inc (ANGO) | $170.82 Million | 0.00% | 0.56x | $648.09 Million |
| Akoya Biosciences Inc (AKYA) | $53.77 Million | -117.77% | 2.35x | $64.44 Million |
| Align Technology Inc (ALGN) | $3.60 Billion | 10.04% | 0.65x | $10.53 Billion |
| AptarGroup Inc (ATR) | $313.30 Million | 11.39% | 0.78x | $7.66 Billion |
| AtriCure Inc (ATRC) | $483.76 Million | 10.38% | 0.27x | $2.21 Billion |
| Avinger Inc (AVGR) | $4.24 Million | -1323.46% | 11.63x | $1.52 Million |
| Avantor Inc (AVTR) | $5.57 Billion | -9.53% | 1.12x | $9.19 Billion |
| Azenta Inc (AZTA) | $1.21 Billion | 5.34% | 0.28x | $1.45 Billion |
| Baxter International Inc (BAX) | $2.83 Billion | 11.40% | 1.70x | $12.26 Billion |
| Becton Dickinson and Company (BDX) | $5.43 Billion | 24.24% | 0.78x | $48.93 Billion |
About AngioDynamics Inc
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vesse… Read more